Breaking News, Financial News

Financial Report: Roche

Pharmaceutical sales up 3% in the quarter, driven by Tecentriq, Hemlibra, Ocrevus and Perjeta.

By: Contract Pharma

Contract Pharma Staff

Roche 1Q Revenues: 15.1 billion CHF (+2%) Comments: Pharmaceutical sales were 12.3 billion CHF, up 3% in the quarter. Key growth drivers in the quarter were the cancer medicine Tecentriq, the haemophilia medicine Hemlibra, the multiple sclerosis medicine Ocrevus and the breast cancer medicine Perjeta, partially offset by competition from biosimilars. Avastin sales were 1.5 billion CHF, down 13%. MabThera/Rituxan sales were down 15% to 1.4 billion CHF. Herceptin sales were down 24% to 1.2...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters